SEC Form 4 · accession 0001209191-16-140964
Arcadia Biosciences, Inc. · RKDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew T Plavan
Officer — Chief Financial Officer
Period of report
Sep 12, 2016
Accepted (ET)
Sep 12, 2016 · 5:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001469443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.17 | Sep 12, 2016 | A | 125,000 | A | — | Sep 11, 2026 | Common Stock | 125,000 | 125,000 | D |
| Stock Option (right to buy)F1 | $6.00 | Sep 12, 2016 | A | 150,000 | A | — | Sep 11, 2026 | Common Stock | 150,000 | 150,000 | D |
| Stock Option (right to buy)F1 | $8.00 | Sep 12, 2016 | A | 150,000 | A | — | Sep 11, 2026 | Common Stock | 150,000 | 150,000 | D |
| Stock Option (right to buy)F1 | $12.00 | Sep 12, 2016 | A | 37,500 | A | — | Sep 11, 2026 | Common Stock | 37,500 | 37,500 | D |
| Stock Option (right to buy)F1 | $15.00 | Sep 12, 2016 | A | 37,500 | A | — | Sep 11, 2026 | Common Stock | 37,500 | 37,500 | D |
Explanation of responses
- F125% of the total number of shares subject to the option will vest on 9/12/2017; the remaining 75% of the total number of shares subject to the option will vest in 36 equal installments, with the first installment occurring 9/30/2017, and thereafter on the last day of the month for the next 35 months.